Purple BiotechPurple Biotech
  • Home
  • About us
    • Our History
    • Mission
    • Executive Team
    • Board of Directors
    • Scientific Advisory Board
  • Pipeline
    • Overview
    • CAPTN-3
    •     IM1240
    •     IM1305
    • Publications
  • Investors
    • Overview
    • News & Events
    • Press Releases
    • SEC Filings
    • Shareholders’ Meetings
    • Email Alerts
    • Corporate Governance
  • Contact us
menu
  • Home
  • About us
  • Pipeline
  • Investors
  • Contact Us
To Top

Category: News and Events

Categories

  • News and Events
    • Events
    • News
  • Publications
    • CAPTN-3
    • CM-24
    • more about CM-24
    • more about NT-219
    • NT-219

Posts

  • Purple Biotech to Present New Preclinical Data of IM1240 at the European Association for Cancer Research (EACR) 2026 Annual Congress which takes place June 8-11, 2026 in Budapest, Hungary.
  • Toxicology study results in NHP validated improved PK and safety profile of CAPTN-3 masking design, revealing an extended therapeutic window
  • Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress which takes place December 10-12, 2025 in London, UK.
  • CAPTN-3 unique design demonstrated by 2 novel platform trispecific T Cell engagers
  • Purple Biotech will participate in a fireside chat and 1×1 investor meeting at the H.C. Wainwright 27th Annual Global Investment Conference, being held September 8-10, 2025.
  • CAPTN-3: A novel platform of conditionally activated T cell and NK cell engagers
  • Final results of the randomized Phase 2 of CM24 in pancreatic cancer: Improved outcomes and significant efficacy in a serum biomarker-enriched subgroup
  • APC-loss as a potential biomarker for NT219 treatment in colorectal cancer
  • NT219 overcomes immune evasion mechanisms in head and neck squamous cell carcinoma (HNSCC)
  • Purple Biotech to Participate in Panel Discussion at Canaccord Genuity Horizons in Oncology Virtual Conference on April 7, 2025
Purple Biotech to Present New Preclinical Data of IM1240 at the European Association for Cancer Research (EACR) 2026 Annual Congress which takes place June 8-11, 2026 in Budapest, Hungary.

Purple Biotech to Present New Preclinical Data of IM1240 at the European Association for Cancer Research (EACR) 2026 Annual Congress which takes place June 8-11, 2026 in Budapest, Hungary.

By PurpleDev1
in
Events
Jun 16, 2026
Read more
Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress which takes place December 10-12, 2025 in London, UK.

Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress which takes place December 10-12, 2025 in London, UK.

By PurpleDev1
in
Events
Dec 22, 2025
Read more
Purple Biotech will participate in a fireside chat and 1×1 investor meeting at the H.C. Wainwright 27th Annual Global Investment Conference, being held September 8-10, 2025.

Purple Biotech will participate in a fireside chat and 1×1 investor meeting at the H.C. Wainwright 27th Annual Global Investment Conference, being held September 8-10, 2025.

By PurpleDev1
in
Events
Aug 27, 2025
Read more
Purple Biotech to Participate in Panel Discussion at Canaccord Genuity Horizons in Oncology Virtual Conference on April 7, 2025

Purple Biotech to Participate in Panel Discussion at Canaccord Genuity Horizons in Oncology Virtual Conference on April 7, 2025

By PurpleDev1
in
Events
Apr 02, 2025
Read more
Purple Biotech to participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference, on September 9-11

Purple Biotech to participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference, on September 9-11

By PurpleDev1
in
Events
Sep 05, 2024
Read more
OncLive video: Michael Cecchini, MD, discusses Purple Biotech’s Phase 2 interim data on the use of CM24 with nivolumab and NALIRIFOX in advanced/metastatic pancreatic ductal adenocarcinoma.

OncLive video: Michael Cecchini, MD, discusses Purple Biotech’s Phase 2 interim data on the use of CM24 with nivolumab and NALIRIFOX in advanced/metastatic pancreatic ductal adenocarcinoma.

By PurpleDev1
in
News
Aug 13, 2024
Read more
Purple Biotech to host a virtual KOL event on July 11, 2024, to discuss positive interim results from the phase 2 pancreatic cancer study with CM24. Watch here.

Purple Biotech to host a virtual KOL event on July 11, 2024, to discuss positive interim results from the phase 2 pancreatic cancer study with CM24. Watch here.

By PurpleDev1
in
Events
Jul 04, 2024
Read more
The Cancer Letter “In Brief” newsletter article about CM24 positive interim results presented at ASCO 2024: “CM24 combination improves clinical outcomes in advanced metastatic PDAC in phase II study interim data”

The Cancer Letter “In Brief” newsletter article about CM24 positive interim results presented at ASCO 2024: “CM24 combination improves clinical outcomes in advanced metastatic PDAC in phase II study interim data”

By PurpleDev1
in
News
Jun 13, 2024
Read more
Fierce Biotech coverage on CM24 positive interim Phase 2 results presentation at ASCO 2024: “ASCO: Early Purple data gain ground in metastatic pancreatic cancer”

Fierce Biotech coverage on CM24 positive interim Phase 2 results presentation at ASCO 2024: “ASCO: Early Purple data gain ground in metastatic pancreatic cancer”

By PurpleDev1
in
News
Jun 03, 2024
Read more

Purple Biotech will present data from the Randomized Phase 2 CM24 Pancreatic Cancer Study in a Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting which takes place May 31 – June 4, 2024 in Chicago, Illinois.

By PurpleDev1
in
Events
May 15, 2024
Read more
1 2 3 Next »
Corporate Headquarters

4 Oppenheimer St.
Science Park, Rehovot
Israel 7670104
Tel : + 972-3-9333121

ir@purple-biotech.com

 

Follow Us
linkedin
Purple biotech
  • Investors
  • Pipeline
  • About us
  • Contact Us

2026 All Rights Reserved. Created BY ATEAS.BIZ

  • Home
Skip to content
Open toolbar Accessibility Tools

Accessibility Tools

  • Increase TextIncrease Text
  • Decrease TextDecrease Text
  • GrayscaleGrayscale
  • High ContrastHigh Contrast
  • Negative ContrastNegative Contrast
  • Light BackgroundLight Background
  • Links UnderlineLinks Underline
  • Readable FontReadable Font
  • Reset Reset
We utilize cookies to improve our site and your experience when using it. To find more details, and to know how we obtain, store, and work with your personal data, check our Privacy Policy page.
You can revoke your consent any time using the Revoke consent button.